This month we have selected two phase-2 trials investigating α-synuclein-binding antibodies as potential disease-modifying treatment of Parkinson’s disease.
Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.
Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.
The Innovative Health Initiative, a public-private partnership between the European Union and the European life science industries, has launched its first call for proposals, including a topic focusing on neurodegenerative diseases.
Our research paper of the month is a meta-analysis investigating the influence of intraventricular fibrinolysis on functional outcomes in patients with intracerebral haemorrhage.
Our authors of the month conducted this study in which COVID-19 patients with neurological symptoms and cognitive impairments, underwent DMI in the subacute stage of the disease.
The EAN Scientific Panel on Palliative Care has been considering the collaboration between neurology and palliative care, particular in the care of people with progressive neurological disease.